Allogene Therapeutics, Inc. (NASDAQ:ALLO) has 166 institutional investors with active 13F positions as of December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Pfizer Inc | 31 Mar, 2026 | 22,032,040 | 0 | 0.00% | $49,792,410.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 19,091,095 | 1,415,066 | 8.01% | $46,582,273.00 |
| TPG GP A, LLC | 31 Mar, 2026 | 18,716,306 | 0 | 0.00% | $45,667,787.00 |
| State Street Corp | 31 Mar, 2026 | 8,660,306 | 5,898,906 | 213.62% | $21,131,147.00 |
| PRIMECAP MANAGEMENT CO/CA/ | 31 Mar, 2026 | 8,379,840 | 240,000 | 2.95% | $20,446,810.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 6,921,350 | 6,921,350 | 0.00% | $16,888,094.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 6,793,620 | -5,317,800 | -43.91% | $16,576,432.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 5,380,902 | 5,380,902 | 0.00% | $13,130.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 5,375,456 | 1,952,015 | 57.02% | $13,116,113.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 4,124,178 | 191,268 | 4.86% | $10,065,365.00 |
| Frazier Life Sciences Management, L.P. | 31 Mar, 2026 | 3,796,668 | -72,082 | -1.86% | $9,263,870.00 |
| Woodline Partners LP | 31 Mar, 2026 | 3,501,078 | 579 | 0.02% | $8,542,630.00 |
| Patient Square Capital LP | 31 Mar, 2026 | 3,450,000 | -1,513,756 | -30.50% | $8,418,000.00 |
| MARSHALL WACE, LLP | 31 Mar, 2026 | 3,447,984 | 3,162,423 | 1,107.44% | $8,413,082.00 |
| MILLENNIUM MANAGEMENT LLC | 31 Mar, 2026 | 3,322,053 | 1,480,746 | 80.42% | $8,105,809.00 |
| Candriam S.C.A. | 31 Mar, 2026 | 2,997,318 | 691,674 | 30.00% | $7,313,456.00 |
| Wildcat Capital Management, LLC | 31 Mar, 2026 | 2,920,787 | 0 | 0.00% | $7,126,720.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 2,766,244 | -1,812,672 | -39.59% | $6,749,636.00 |
| D. E. Shaw & Co., Inc. | 31 Mar, 2026 | 2,763,776 | 1,480,805 | 115.42% | $6,743,613.00 |
| Boxer Capital Management, LLC | 31 Mar, 2026 | 2,725,000 | 2,725,000 | 0.00% | $6,649,000.00 |